Insider Selling: Artiva Biotherapeutics (NASDAQ:ARTV) CEO Sells $422,000.64 in Stock

Posted by Stanley Muller on Oct 6th, 2026

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) CEO Fred Aslan sold 61,696 shares of Artiva Biotherapeutics stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $6.84, for a total value of $422,000.64. Following the completion of the transaction, the chief executive officer directly owned 1,543,069 shares in the company, valued at approximately $10,554,591.96. This represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Fred Aslan also recently made the following trade(s):

On Tuesday, September 8th, Fred Aslan sold 23,429 shares of Artiva Biotherapeutics stock. The shares were sold at an average price of $10.92, for a total transaction of $255,844.68.

Artiva Biotherapeutics Trading Up 2.0%

NASDAQ:ARTV traded up $0.14 on Tuesday, reaching $7.27. 664,480 shares of the stock traded hands, compared to its average volume of 393,650. Artiva Biotherapeutics, Inc. has a 1-year low of $2.71 and a 1-year high of $14.53. The company’s 50 day moving average is $10.09 and its 200-day moving average is $9.22. The firm has a market capitalization of $355.43 million, a price-to-earnings ratio of -2.20 and a beta of 2.40.

Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.63). On average, equities research analysts forecast that Artiva Biotherapeutics, Inc. will post -2.62 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $40.00 price target on shares of Artiva Biotherapeutics in a report on Friday. Needham & Company LLC reissued a “buy” rating and issued a $41.00 price objective on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. Finally, HC Wainwright restated a “buy” rating on shares of Artiva Biotherapeutics in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

Get Our Latest Report on Artiva Biotherapeutics

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ARTV. BlackRock Inc. acquired a new stake in Artiva Biotherapeutics in the second quarter worth $6,739,000. ADAR1 Capital Management LLC acquired a new position in shares of Artiva Biotherapeutics during the second quarter valued at about $1,151,000. Nantahala Capital Management LLC acquired a new position in shares of Artiva Biotherapeutics during the second quarter valued at about $2,910,000. Alyeska Investment Group L.P. boosted its position in shares of Artiva Biotherapeutics by 173.6% during the 2nd quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company’s stock worth $2,654,000 after purchasing an additional 173,615 shares in the last quarter. Finally, Blue Owl Capital Holdings LP bought a new position in shares of Artiva Biotherapeutics during the 2nd quarter worth about $8,483,000.

About Artiva Biotherapeutics

(Get Free Report)

Artiva Biotherapeutics, Inc (NASDAQ:ARTV) is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is designed to produce off-the-shelf cell therapies that can be manufactured at scale and administered without using cells collected from each individual patient.

Artiva’s lead investigational product, AlloNK, also known as AB-101, is an allogeneic NK cell therapy being evaluated in combination with rituximab for autoimmune conditions, including systemic lupus erythematosus and lupus nephritis.